and 34). Applicants herewith cancel the nonelected claims pending the filing of two divisionals on the nonelected subject matter.

The examiner correctly observes that the presently elected claims fall within the scope of the parental allowed claims and the claimed subject matter is expressly disclosed in the parent. Accordingly, the examiner has called for the filing of a terminal disclaimer over the term of any patent issuing on the parent (which has been allowed). A terminal disclaimer meeting these requirements is submitted herewith, together with a deposit account authorization for the required fee.

The examiner also noted copending USSN 08/900,752 (Gilead docket no. 230). Applicants' representative pointed out that that case was directed to a specific salt of the presently claimed compounds. The salt (fumarate) offers particular advantages and thus constitutes an independent improvement, separately patentable over the subject matter herein claimed.

This application now should be in condition for allowance. An early notice to that effect is solicited.

Respectfully submitted,

Max Hensley, Reg. No. 27,04

Gilead Sciences, Inc. 333 Lakeside Drive

Foster City, CA 94404

Telephone: (650) 522-5878 Facsimile: (650) 522-5899

E-mail: Max_Hensley@Gilead.com

Date: April 21, 1999